Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 1 Sept 2020

Balasubramanian Adithya, Gunjur Ashray, Gan Hui Kong, Perchyonok Yuliya, Cher Lawrence Myron

Abstract excerpt

Pilocytic astrocytomas are World Health Organisation (WHO) grade I tumors, occurring predominantly supratentorially and in the pediatric population. Although the mainstay of treatment is local therapies such as surgery, targeted systemic therapies may be necessary for recurrent or unresectable disease. The majority of sporadic pilocytic astrocytomas are associated with the BRAF-KIAA fusion gene, which results in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Spinal Cord Neoplasms

Source

Identifiers

PMID: 33070910
DOI: 10.1016/j.jocn.2020.07.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.PMID 33070910Read ↗

Impact of BRAF/MEK inhibitor on BRAF V600E-mutated pilocytic astrocytoma.Semantic proximity Read ↗

Adult pilocytic astrocytomas: clinical features and molecular analysis.Semantic proximity Read ↗

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.Semantic proximity Read ↗

V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior.Semantic proximity Read ↗

BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.Semantic proximity Read ↗

MAPK pathway activation in pilocytic astrocytomaSemantic proximity Read ↗

Pilocytic astrocytoma: pathology, molecular mechanisms and markers.Semantic proximity Read ↗

Pilocytic astrocytoma in adults: Histopathological, immunohistochemical and molecular study with clinical association.Semantic proximity Read ↗

Concomitant KIAA1549-BRAF fusion and IDH mutation in Pediatric spinal cord astrocytoma: a case report and literature review.Semantic proximity Read ↗

The involvement of the MAPK pathway in pilocytic astrocytomas.Semantic proximity Read ↗

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.Semantic proximity Read ↗

MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a Young Adult Patient: A Case Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.